Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome

Pelvic Congestion Syndrome (PKS) is generally seen in female patients of reproductive age and is characterized by abdominopelvic pain and a feeling of fullness in the perineum and vulva. Patients may also be accompanied by dysmenorrhea , dyspareunia, postcoital pain, dysuria , hematuria, waist and hip pain. The pain usually increases with standing and decreases with lying down. PCS is one of the causes of chronic pelvic pain (CPA). As in CPA , it lasts longer than 6 months and is independent of the menstrual cycle. Its etiopathogenesis has not been fully elucidated. at PKS There is dilatation in the ovarian veins. In the current definition, diseases that involve dilatation of the veins in the pelvic region and were referred to by different names in the past are called Pelvic Venous Disease .

There is no consensus on the diagnostic criteria for PCS . Catheter venography along with the patient's clinical findings is still the gold standard in diagnosis. Among non- invasive methods , >0.6 mm dilatation in the ovarian veins on transvaginal or transabdominal ultrasound (USG) is one of the most important findings of PCS .

There have been significant changes in its treatment in recent years. Some of the hormone treatments used in the 1980s were abandoned due to their side effects. Some flavonoid fraction drugs are used in PCS due to their vasoactive effects . Anti-inflammatory drugs, paracetamol, are preferred for analgesic purposes , and gabapentinoids and antidepressants are preferred for central sensitization . In the same years, hysterectomy and single or bilateral oophorectomy were performed by gynecologists. Laparoscopic ovarian vein ligation began to be performed in the 2000s , but it lost its popularity due to serious complications such as hematoma in the retroperitoneum and ureteral injury . Today, some endovascular sclerosing drugs, foam, plug and coil embolization techniques are frequently used alone or in combination in the treatment of PCS . There are studies on the low complications and high effectiveness of these treatments .

Diagnosis and treatment of PCS patients, who frequently apply to urology and gynecology, are often delayed, patients are followed up with different diagnoses, and the cost increases. Endovascular intervention is a minimally invasive technique and patients are discharged on the same day. There are approximately 3 times more studies in the literature ( PUBMED, EMBASE, MEDLINE (OVID), Web of Science ) on coil embolization , one of the endovascular methods used , than on plug treatment (9). We aimed to contribute to the limited literature on the effectiveness of plug therapy in PCS patients with limited access to diagnosis and treatment .

Study Overview

• Status: Completed
• Conditions: Pain, Chronic
• Intervention / Treatment: Other: Endovascular Plug Embolization

Detailed Description

Patients diagnosed with pelvic congestion syndrome who underwent endovascular procedures using the plug method in the cardiovascular surgery clinic of our hospital between January 2023 and March 2024 were examined. The study was conducted in accordance with the Declaration of Helsinki. The study was conducted retrospectively with 32 patients who met the criteria.

18 years of age , with abdominopelvic pain for more than 6 months , with clinical, physical examination and symptoms , and with >6 mm dilatation in the pelvic veins on transvaginal or transabdominal ultrasound (USG) were included in the study. It was performed by a radiologist with at least 10 years of experience in the field of USG.

Gynecologically, patients with leiomyoma, pelvic inflammatory disease, endometriosis , postoperative adhesion, patients who have undergone urological and gynecological surgery, patients with chronic renal failure, patients with known allergies to the drugs used during the procedure , patients with abdominopelvic trauma, malignancy or its history, patients with a history of radiotherapy chemotherapy, patients with known psychiatric disease, Pregnant women, breastfeeding women, patients with fibromyalgia , known lumbar disc herniation, scoliosis, facet syndrome, sacroiliac dysfunction, and patients with genitourinary and gastrointestinal diseases were excluded from the study.

Patients' age, body mass index (BMI), painful areas (perineum, vulva, labia major/minor, hypogastrium , inguinal region, hip, waist, leg) and painful side, medical treatments, additional diseases, onset of pain and application for endovascular intervention. duration, symptoms accompanying pain ( feeling of heaviness in the perineum , labia swelling in the majora , Dysuria , Hematuria, Dyspareunia , Postcoital pain, Dysmenorrhea , frequent urination) In which position does the pain increase: lying down: (supine / prone / lateral) standing / sitting, presence of varicose veins in the lower extremity , vein entered during endovascular intervention, embolized vein, embolotherapy type, procedure time (min), cumulative radiation exposure during the procedure (mGy- m2 ) Complications observed during the procedure (Vessel perforation / Hematoma / Phlebitis / Embolism / Migration / Vasovagal / Dyspnea / Panic attack / Allergy / Infection) and the need for repeated procedures were recorded in the patient follow-up form.

For pain and functionality evaluation, NRS-11 scores and SF-12 scores were recorded before and at the first and third months after the endovascular procedure.

1. Numeric Rating Scale-11 ( NRS - 11 ) is an 11-point numerical scale where patients can evaluate their pain between 0 (no pain) and 10 (the most severe pain they have ever felt in their life) .
2. Short form-12 (SF-12): It is a scale that evaluates patients' quality of life levels. Short Form-12 is the abbreviation of Short Form-36. In SF-12, the patient's general health status, physical and mental functions, quality of life and social activities are questioned. It is scored between 0-100. A high score is associated with good general health status. It is a validated scale. This test was applied 3 times: before treatment, 1 month and 3 months after treatment.

• Study Type: Observational
• Enrollment (Actual): 44

Contacts and Locations

Study Locations

• Turkey (Türkiye)
  • Istanbul, Turkey (Türkiye), 34000
    • Kanuni Sultan Suleyman Training and Research Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Inclusion Criteria:

• 18 years of age
• with abdominopelvic pain for more than 6 months ,
• with clinical, physical examination and symptoms , and with >6 mm dilatation in the pelvic veins on transvaginal or transabdominal ultrasound (USG) were included in the study.
• It was performed by a radiologist with at least 10 years of experience in the field of USG

Description

exclusion criteria: -Gynecologically, patients with leiomyoma, pelvic inflammatory disease, endometriosis , postoperative adhesion,

• Patients who have undergone urological and gynecological surgery,
• Patients with chronic renal failure,
• Patients with known allergies to the drugs used during the procedure ,
• Patients with abdominopelvic trauma, malignancy or its history,
• Patients with a history of radiotherapy chemotherapy,
• Patients with known psychiatric disease,
• Pregnant women,
• Breastfeeding women,
• Patients with fibromyalgia ,
• Known lumbar disc herniation, scoliosis, facet syndrome, sacroiliac dysfunction, and patients with genitourinary and gastrointestinal diseases were excluded from the study.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome	Other: Endovascular Plug Embolization; Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
onset of pain and application time for endovascular intervention	'four months'

Collaborators and Investigators

• Sponsor: Halil Ibrahim Altun

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2024
• Primary Completion (Actual): September 1, 2024
• Study Completion (Actual): September 30, 2024

Study Registration Dates

• First Submitted: August 11, 2024
• First Submitted That Met QC Criteria: August 11, 2024
• First Posted (Actual): August 14, 2024

Study Record Updates

• Last Update Posted (Actual): January 8, 2026
• Last Update Submitted That Met QC Criteria: January 6, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Pelvic Congestion Syndrome, Pain,chronic pelvic pain
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Chronic Pain
• Other Study ID Numbers: ibrahim

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No